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SUPPLEMENTARY NOTES
ABSTRACT:
The objective of our work was to study the role of cell-ECM interactions in the increased survival, migratory and invasive phenotype found in the transition from DCIS to invasive carcinoma. We considered the possibility that loss of tissue architecture could elicit malignant transformation via integrin-growth factor receptor-regulated ERK effects on growth and survival as well as on angiogenesis, probably through a close interaction between tumor cells and macrophages. Ectopic expression of 5 1 integrin enhanced invasion, migration and survival of the premalignant S3-C cells in vitro, as well as increasing their malignant phenotype in vivo in nude mice. We proposed that 5 1 integrin could be affecting the cells phenotype via induction of the flt-1 VEGFR expression, which would participate in an autocrine survival loop. The enhanced malignant phenotype in vivo was characterized by an angiogenic switch, correlated with increased macrophage infiltration of the tumor. In vitro experiments suggest that this increase in angiogenesis potential might involve a paracrine loop between macrophages and MECs, in which macrophage-derived EGF induces an increase in IL-8 expression by MECs, which in turn increases their angiogenic ability.
SUBJECT TERMS
Breast cancer, angiogenesis, extracellular matrix, tissue architecture, alpha5beta1 integrin, fibronectin, VEGF, Interleukin-8, VEGF receptor 1, autocrine survival loop, uPA receptor, dormancy
INTRODUCTION:
Since the exponential growth of new DCIS cases found during the last few years, which have recently reached epidemic proportions, understanding how a DCIS lesion evolves into an invasive tumor and finally gives rise to metastatic foci is fundamental for establishing a way to control the progression of breast cancer. To become a malignant tumor, cells from a DCIS lesion have to be able to invade the surrounding stroma. Consistently, breast cancer development from a DCIS is characterized by perturbations in stromal-epithelial interactions, and mammary tumors and cell lines characteristically exhibit alterations in their integrin expression when compared to cells from premalignant lesions (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Moreover, during malignant transformation of the breast, there is an increase in FN and TN levels in the stroma, and breast tumors often show an increase in 5 1 and v (x) integrin expression (10) (11) (12) (13) (14) (15) . This suggests that integrins might be playing an important role in malignant transformation of the breast.
The objective of our work was to study the role of cell-ECM interactions in the increased survival, migratory and invasive phenotype found in the transition from normal breast to pre-malignant lesion and from DCIS to invasive carcinoma. We considered the possibility that loss of tissue architecture could elicit malignant transformation via integrin-growth factor receptor-regulated ERK/ AKT effects on growth and survival as well as on angiogenesis, probably through a close interaction between tumor cells and macrophages.
BODY:
In the first two years of this grant we established that malignant transformation and breast cancer behavior is associated with 5 1 integrin over expression, and that inhibition of this receptor can induce a state of tumor dormancy that is tightly linked to tissue architecture. Inhibition of 5 1 integrin activity in tumor cells repressed tumor growth, and this was linked to inhibition of angiogenesis. Similarly, ectopic expression of 5 1 integrin by the nonmalignant S1 cells induced loss of tissue structure (hyperplasia) in vivo, and loss of polarity in 3D rBM+FN by these cells. This was also correlated with an increased angiogenic phenotype. Using the S3-C cells as a model of DCIS in vitro we sought to study how tumor progression occurs in vivo and to determine which molecules are functionally significant for transition from premalignancy to malignancy. In particular, we wanted to assess the role of 5 1 integrin in malignant transformation of the breast.
Ectopic expression of 5 1 integrin enhanced invasion, migration and survival of the premalignant S3-C cells in vitro, as well as increasing their malignant phenotype in vivo in nude mice. We proposed that 5 1 integrin could be affecting the cells phenotype via induction of the flt-1 VEGFR expression, which would participate in an autocrine survival loop. The enhanced malignant phenotype in vivo was characterized by an angiogenic switch, correlated with increased macrophage infiltration of the tumor. In vitro experiments suggest that this increase in angiogenesis potential might involve a paracrine loop between macrophages and MECs, in which macrophage-derived EGF induces an increase in IL-8 expression by MECs, which in turn increases their angiogenic ability.
With these studies we can report significant progress on all three of the specific aims and the tasks detailed in my SOW:
1) To determine if there is a correlation between tumorigenicity, loss of acinar structure, v and/or 5 integrin expression and angiogenesis. 2) To test if the reacquisition of a polarized acinar structure is related to the loss of the angiogenic phenotype and if this is linked to changes in v and/or 5 integrin. 3) To determine if the up-regulation of v and/or 5 integrins is a predictor of malignant behavior in HMT-3522 MECs, and functions by compromising tissue organization and inducing angiogenesis and invasion.
1. Our first aim was to determine if there is a correlation between tumorigenicity, loss of acinar architecture and angiogenesis.
We previously showed that when the cells in our model progress towards malignancy, they present altered tissue architecture including cell-cell interactions, integrin expression and organization, ECM expression and deposition and expression of proangiogenic molecules such as VEGF and IL-8 (Fig 1a, b and 2c ). Using our 3D multicellular MEC rBM/collagen I EC model we observed an increased angiogenic ability correlated with tumor progression in vitro (Fig 2b) . When the cells in our model were injected into nude mice for in vivo angiogenesis and tumor studies, we were able to further confirm their angiogenic phenotype in vivo (Fig 2a) .
Due to the consistency of the data obtained in our in vitro as well as in vivo angiogenesis studies, we decided not to do the acute angiogenesis assays to avoid the unecessary use of animals.
Our second aim was to test if tumor reversion and reformation of a "differentiated" tissue-like structure is associated with repression of angiogenic behavior and to determine if this is linked to altered expression and/or activity of 5 and v integrin.
We found that phenotypic reversion of the tumors using EGFR inhibitor and 1-integrin function blocking mAb in the 3D rBM assay induced normalization of the integrin expression profile (Fig 3b) , on ECM protein expression (inhibiting FN deposition; Fig 3a) and inhibiting the expression of VEGF and IL-8 in the tumor cells (Fig 5e, f) . To specifically test the importance of altering v and 5 integrins in the reverted tumor phenotype we inhibited v and 5 integrins using function-blocking mAbs. We found that by blocking 5 integrin activity we could induce a state of tumor dormancy similar to the one achieved by blocking 1 integrin function (Fig 3c, d ). We determined that 5 1 integrin-FN interaction regulates ECM deposition, angiogenic molecule expression (Fig 5 e, f) and tissue organization in 3D rBM cultures, as well as the tumor cells angiogenic behavior in vitro (in the 3D multi-cellular MEC assay; Fig  5c) .We showed that 5 1 integrin sustains tumorigenicity and angiogenesis in vivo (Fig  5a, b) .
By inducing 5 integrin over-expression in the T4-2 cells using an exogenous retroviral promoter we determined that exogenous over-expression of 5 integrin interferes with EGFR inhibitor-tumor reversion potential, increasing 10 times the amount of EGFR inhibitor necessary to induce their phenotypic reversion (not shown). While the inhibition of 5 integrin function in T4-2 cells induced their reversion to a polarized state (basal deposition of 4 integrin and ECM proteins and apicolateral deposition ofcatenin) over-expression of 5 integrin in these cells did not affect their phenotype in 3D rBM (not shown). Since over expression of 5 integrin by T4-2 cells also had no effect on their proliferation, motility, or invasiveness in the transwell assay, we decided not to continue with the following specific aims (f-n) and focused instead in other important modulators of tumor growth which had been shown to be linked to 5 1 integrin such as uPAR and EGFR that had not been included in the original SOW.
Tumor dormancy has been tightly linked to urokinase-type plasminogen activator receptor (uPAR) deficit, and uPAR levels increase in cancer (16) . Moreover, it has been shown that 5 1 integrin-uPAR interaction through EGFR is required for tumor growth in vivo, and that interfering with any of these receptors can induce tumor dormancy in hepatocarcinoma cells (17). Based on these data, we decided to evaluate the molecules involved in the regulation of malignant progression and tumor dormancy. Specifically, we studied the uPAR status in the HMT-3522 cell series and found that 5 integrin expression induces the expression of uPAR, and determined via function blocking studies that this receptor is involved in tissue architecture-mediated tumor dormancy through regulation of angiogenesis (Fig 6) .
Our third aim was to determine if over expression of v-and/or 5-integrins would be sufficient to drive invasive and angiogenic behavior in either pre malignant or non malignant MECs and whether this is associated with disruption of cell-cell interactions, perturbations in tissue polarity and is mediated through effects on angiogenic regulator molecules.
We achieved this goal by directly up-regulating the expression of v, 2 and 5 integrins in the nonmalignant S1 and pre-malignant S3 cells using inducible retroviral expression constructs and assayed for effects on tissue architecture, invasion and expression of angiogenic molecules using the 3D rBM assay.
In the S1 non-malignant cells, we found that 5 1 integrin expression and ligation was enough to induce loss of tissue polarity promoting an angiogenic switch, although not enough to induce invasion (Fig 4 and 5) . We used the multi-cellular 3D model to assess the cells angiogenic and invasive behavior ex vivo and tumor injections in nude mice to study in vivo tumorigenicity and angiogenesis and confirmed again that 5 1 integrin expression and ligation induces an angiogenic phenotype both in vitro as well as in vivo, and induces loss of the normal phenotype in the nonmalignant S1 cells, which give rise to hyperplastic lesions (Fig 5) .
Finally, ectopic expression of 5 1 integrin enhanced invasion, migration and survival of the premalignant S3-C cells in vitro, as well as increasing their malignant phenotype in vivo in nude mice (Fig 7) . There is evidence showing that increased survival of breast cancer cells might involve an autocrine loop in which VEGF-activated VEGFR can repress apoptosis and enhance growth (18). We found expression of 5 1 integrin to induce increased survival of the pre-malignant cells by inducing the expression of VEGFR-1 (Fig 7f) . This receptor was linked to increased survival, since its inhibition inhibited the cells ability to grow anchorage independently in soft agar (Fig 7g) . Expression of 5 1 integrin also increased the S3 cells' angiogenic ability in vivo (Fig 8a) . This correlated with a higher macrophage infiltration of the S3 5-derived tumors. Premalignant S3 cells already express high levels of VEGF, thus, 5 integrin did not affect the expression of this molecule. Surprisingly, EGF induced the expression of IL-8 only in the context of 5 1 integrin-expressing cells (Fig 8c) . These data, together with the finding that S3 5 cells-derived tumors had a higher macrophage infiltration, confirmed that 5 1 integrin-EGFR interaction is important for malignant progression and suggested that a paracrine loop involving macrophages and MECs could be taking place, in which macrophage-derived EGF induces an increase in IL-8 expression by MECs, which in turn increases their angiogenic ability.
KEY RESEARCH ACCOMPLISHMENTS:
• In vivo characterization of S3 cells regarding their malignant and their angiogenic phenotype.
• Expression characterization of protein by FACs analysis in S-3 cells expressing 5, v and 2 integrins. In 2D monolayer.
• Immunological characterization of S-3 cells expressing 5, v and 2 integrins in 3D
rBM.
• Invasion characterization of S-3 cells expressing 5 integrin.
• Angiogenesis characterization of S-3 cells expressing 5 integrin in co-cultures. 
REPORTABLE OUTCOMES for the last period:
Products
CONCLUSIONS:
In conclusion, the data presented here suggest that 5 1 integrin is involved in the conversion from a normal to a premalignant phenotype and that inhibition of 5 1 integrin function can render a tumor dormant. This, together with our finding that 5 1 integrin also plays a fundamental role in the transition from pre-malignancy to malignancy, suggests that 5 1 integrin has a very prominent role in malignant transformation.
This work also demonstrated a putative link between uPA-uPAR and 5 1 integrin expression that could be involved in the loss of tissue architecture and development of metastasis. In fact, 5 1 integrin is found in metastatic breast disease as well as other tumors that metastasize, and it has been postulated that it may be promoting angiogenesis through regulation of VEGF -and via loss of tissue integrity -. This could be also true for the link that we found between 5 1 integrin expression, tumor progression and IL-8 expression. Surprisingly, EGF induced the expression of IL-8 only in the context of 5 1 integrin-expressing cells. These data, together with the finding that S3 5 cells-derived tumors had a higher macrophage infiltration, confirmed that 5 1 integrin-EGFR interaction is important for malignant progression and suggested that a paracrine loop involving macrophage-derived EGF and MECs-derived IL-8 could be taking place.
Furthermore, our results indicate that tissue differentiation -architecture mediated dormancy-may be functionally linked to metastatic tumor dormancy mechanisms, suggesting that if we could delineate the molecular mechanisms by which cells acquire dormancy in a tissue this may reveal novel insights into how metastatic tissue dormancy may arise.
Put together, these data imply that there is not just one factor that controls the state of a tumor, but that there are interconnected factors that regulate each other. This are promising results, since they imply that tumor dormancy could be achieved and maintained by various means, giving the cancer patient more chances to win over the tumor. Micrographs showing ECs invasion of collagen layer of co-cultures of HDMVECs and S1 eGFP, S1 2, S1 5, T4-2 and T4 Rvt cells. D. Quantification of average network formation by HDMVECs co-cultured with T4-2 cells in the presence of IgG control, EGFR inhibitor (Rvt) or 1, 5, v or 2 integrin blocking Abs. The same results were obtained in all cases with either iHUVEC2A or HDMVECs. Note that the only cells capable of generating an angiogenic response are the S1 5 and the control T4-2s, and that reverting the tumor phenotype impairs the angiogenic ability of the tumor cells. E. ELISA quantification of VEGF (pg/ml) released to the conditioned media by S1 eGFP and S1 5 cells (left) and T4-2 and T4 Rvt cells (right). F. ELISA quantification of IL-8 
